\n<\/p>\n
Successful Expansion <\/b>into Pharmaceutical
\nE-commerce<\/b> <\/b><\/p>\n
\n
<\/p>\n
\u00a0Driving Sales Growth of <\/b>GeneTime\u00ae<\/b>
\n
<\/p>\n
Achived Significant
\nProgress towards Pipeline Products and Bo<\/b>shutai\u00ae was Granted Approval for
\nMarketing in China<\/b>
\n
<\/p>\n
\u00a0<\/p>\n
\n
<\/p>\n
HONG KONG SAR -
Key Accomplishments
During the Year,
\u00a0<\/p>\n
1.\u00a0\u00a0\u00a0 GeneTime\u00ae (EGF spray
\u00a0<\/p>\n
2.\u00a0\u00a0\u00a0 The Group’s Pinup\u00ae (Voriconazole Tablets) had been
\u00a0<\/p>\n
3.\u00a0 \u00a0 Durning the Year, the Group’s Uni-PTH
\u00a0<\/p>\n
4.\u00a0\u00a0\u00a0
\u00a0<\/p>\n
5.\u00a0\u00a0\u00a0 The Group’s Boshutai\u00ae (Acarbose Tablets) was granted
\u00a0<\/p>\n
6.\u00a0\u00a0\u00a0 During the Year, the Group partnered with Chengdu
\u00a0<\/p>\n
Annual
In 2020, the
\u00a0<\/p>\n
Gross profit slightly
Prospects<\/b><\/p>\n
The COVID-19 pandemic has not only driven the growth of
\u00a0<\/p>\n
Focusing on the Sales of EGF Products<\/b>
The Group’s signature products, GeneTime\u00ae and GeneSoft\u00ae, have been
\u00a0<\/p>\n
Awaiting for Results of Pinup\u00ae in National
The Group submitted the tender application of Pinup\u00ae for
\u00a0<\/p>\n
Focusing on the Commercialization of Acarbose
In 2021, the Group will focus on the commercialization of
\u00a0<\/p>\n
Accelerating the
The Group is optimistic about the potential of Uni-GLP in
\u00a0<\/p>\n
Mr. Kingsley Leung, Chairman of
Successful Expansion into Pharmaceutical
E-commerce
\u00a0Driving Sales Growth of GeneTime\u00ae
Achived Significant
Progress towards Pipeline Products and Boshutai\u00ae was Granted Approval for
Marketing in China
\u00a0
HONG KONG SAR -
EQS Newswire –\u00a030 March 2021 –\u00a0A fully
integrated biopharmaceutical company \u2013 Uni-Bio
Science Group Limited (“Uni-Bio Science”, …<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[60],"tags":[],"_links":{"self":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/13698"}],"collection":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/comments?post=13698"}],"version-history":[{"count":0,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/posts\/13698\/revisions"}],"wp:attachment":[{"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/media?parent=13698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/categories?post=13698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/eodishasamachar.com\/en\/wp-json\/wp\/v2\/tags?post=13698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nEQS Newswire –\u00a030 March 2021 –\u00a0A fully
\nintegrated biopharmaceutical company \u2013 Uni-Bio
\nScience Group Limited<\/a><\/b> (“Uni-Bio Science”, together with its
\nsubsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2020 (the “Year”), as well as its
\ncomparative figures for the year ended 31 December 2019 (“2019”).<\/p>\n
\n
<\/p>\n
\nin 2020<\/b><\/p>\n
\n
<\/p>\n
\nthe Group achieved a spectrum of accomplishments, for both of its marketed
\nproducts and innovative biologics. The key highlights include:<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nindicated for wound healing) generated remarkable results. Sales
\nof GeneTime\u00ae reached HK$137.2 million, representing an increase of 9.5% YoY.
\nThe Group’s newly-developed digital marketing and pharmaceutical e-commerce
\nplatform will continue to be a strong sales driver of GeneTime\u00ae.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nsuccessfully approved by the National Medical Products Administration (“NMPA”) for Bioequivalence (“BE”) certification in December 2020, and
\nhad been included in the national procurement tender on 8 December 2020. The approval would facilitate Pinup\u00ae’s hospital tenders
\nand listings, especially in national procurement, to achieve a larger market
\nshare in the anti-fungal infection drug market.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\n(pre-filled injection pen) or 2nd Generation Uni-PTH was successfully approved
\nby NMPA for clinical trial. The Group will begin conducting bridging clinical
\ntrial for 2nd Generation Uni-PTH. In May
\n2020, the Group started a partnership with Swiss self-care giant Ypsomed to
\nco-develop 2nd Generation Uni-PTH alongside YpsoPen\u00ae, a state-of-the-art pen
\ninjector with unparalleled dosing accuracy which minimized injection pain.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nThe application for clinical trial of
\nRecombinant GLP-1 Injection (“Uni-GLP”)
\nhas been approved by NMPA on 14 July 2020. Currently, the Group’s professional
\nand technical teams are making great efforts in preparing for clinical
\ntrial-related work. Supported by recent data, Uni-GLP has proven its
\ndevelopmental potential in treatment of COVID-19 and other high value
\nindications.<\/p>\n
\n
\n
\n
<\/p>\n
\n
<\/p>\n
\napproval for marketing in China by NMPA on 10 November 2020 and the Group also
\npassed GMP manufacturing inspection and was approved to manufacture Boshutai\u00ae
\nfrom 10 December 2020. To ensure Boshutai\u00ae would be manufactured at
\nthe most competitive cost, the Group formed a strategic partnership with
\nSinopharm Weiqida Pharmaceutical Company Limited and Suzhou Yingli Medical
\nTechnology Company Limited during the Year to lower the production cost,
\nincrease manufacturing efficiency and streamline the overall supply chain.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nMedlinker Technology Company Limited to co-develop digital marketing and
\npharmaceutical e-commerce platform for the Group’s products. Aiming at creating
\nan integrated healthcare system, this corporation is expected to deliver much
\nbetter service for patients and clinical practitioners, expanding its available
\nmarketing channels, and enhancing brand awareness. In addition, the Group is
\nalso proactively exploring partners such as Haodaifu (\u597d\u5927\u592b\u5728\u7dda) and
\nother respective platforms to address the unmet needs for online drug sales.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nResults<\/b><\/p>\n
\n
<\/p>\n
\nGroup recorded a turnover of HK$208.8 million, representing a slight decrease
\nof approximately 0.3% YoY (2019: HK$209.4 million). The decrease in turnover was
\nmainly attribute to the significant sales drop in the first quarter of 2020
\nduring the outbreak of COVID 19. The turnover in the second half exceeded
\nexpectation, and was able to offset most of the shortfall in the first half of
\n2020. Among all the products, GeneTime\u00ae was particularly favoured by the
\nmarket, with an increase of 9.5% in turnover from approximately HK$125.3 million in 2019 to HK$137.2
\nmillion in 2020. The remarkable turnover growth was mainly attributable to the
\nstrong recovery from hospital sales due to efforts of the Group’s broad market
\nteam, as well as the additional turnover from the newly-developed digital
\nmarketing and pharmaceutical e-commerce platform since May 2020. During the
\nYear, GeneSoft\u00ae recorded a decrease in turnover from approximately HK$33
\nmillion in 2019 to HK$31.6 million, representing a decrease of4.2%. The
\ndecrease was mainly attributable to the serious reduction in patients’ hospital
\nvisits since the outbreak of COVID-19, despite there was a gradual recovery in
\nthe second half of the Year. Market competition was keen as Pinup\u00ae did
\nnot received its BE Certification from the NMPA until December 2020. Pinup\u00ae
\nrecorded a decrease of 21.9% in turnover from approximately HK$48.0 million to
\napproximately HK$37.5 million during the Year. The decrease was also attributed
\nto the reduction in patients’ hospital visits due to the COVID-19 outbreak.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\ndecreased 0.2% from approximately HK$181.5 million in 2019 to HK$181.1 million in
\n2020, whereas gross profit margin remained stable at 86.7% (2019: 86.7%). Alongside the ongoing internal control and business optimization by
\ndigitalization, as well as the restructuring of the Group’s sales force and the
\nbuilding of its direct sales team, general and administrative expenses
\n(“G&A Expenses”) decreased for three consecutive years. G&A Expenses
\ndecreased 39.7% yoy from HK$ 59.4 million in 2019 to HK$ 35.8 million in 2020,
\naccounted for 17.2% of turnover as compared with 28.4% in 2019. The
\npercentage of selling and distribution expense over turnover improved to
\naround 70.0% in 2020 from 71.3% in 2019 because of the Group’s cautious
\nsalesforce optimization. R&D expenses slightly decreased by 4.6% to HK$ 40.7<\/a> million
\ndue to the completion of several clinical tests, of which the development
\nexpenses have been capitalized. Operating
\nloss for the Year was HK$ 70.9 million due to an impairment of intangible
\nassets from certain old technologies of previous version products (Uni-PTH and
\nUni-GLP) and an impairment of intangible assets from the unsatisfied BE result
\nand the suspended BE process of Boshutai\u00ae. Excluding the impact of write-off intangible assets and impairment loss on deposit paid for
\nthe acquisition of intangible assets in 2020 together with one off gains from
\ndisposal of property and subsidiary in 2019, the normalised operating loss was
\nsignificantly reduced from HK$62.7 million
\nin 2019 to HK$ 34.8 million
\nin 2020. For 2020, the Group recorded a loss of HK$ 71.3 million (2019: profit
\nof HK$2.5 million), with a basic loss per share of HK 1.11 cents (2019 basic
\nearnings per share: HK0.04 cents).<\/p>\n
\n
\n
\n
<\/p>\n
\n
<\/p>\n
\nthe pharmaceutical industry, but also boosted the online healthcare sector,
\nespecially in China. Regulatory reforms have been introduced to support the
\ndigitalization of the healthcare industry. The Group believes that the
\nfavorable online market environment and government policies would benefit its
\nbusiness operation and promotebusiness growth in the future.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nwell-received by the market. The collaboration with Medlink to develop digital
\nmarketing channels has proved to be successful, as GeneTime\u00ae recorded a
\ntremendous increase in turnover in the second half of 2020. The Group will
\ncontinue to utilize the online resources to promote GeneTime\u00ae. To accommodate
\nthe increasing demand, the Group is planning to expand the production capacity
\nfor its EGF products. New technologies will also be integrated to this new
\nplant to further increase efficiency and decrease production costs. The new
\nsite is expected to commence operations in 2023.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nDrug Volume-based Procurement Which Will Help Secure Future Growth<\/b><\/p>\n
\n
<\/p>\n
\nthe National Drug Volume-based Procurement and has been waiting for the results
\nannouncement. Pinup\u00ae is a voriconazole tablet that is tailored to treat severe
\nfungal infection, and the Group is one of the only two manufactures that has
\npassed BE certification for the 50mg formulation of voriconazole at the end of
\n2020. The Group is confident that Pinup\u00ae will be included in the procurement
\nand believes that the successful inclusion will help meeting the rising demand
\nof anti-fungal medicine in the both public as well as private hospitals, and
\nwill deliver positive impact to the Group’s top and bottom line in the future.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nTablet<\/b><\/p>\n
\n
<\/p>\n
\nBoshutai\u00ae, and expects immediate sales contribution from the product. Meanwhile,
\nthe Group will promote Boshutai\u00ae through third-party channels, including online
\nplatforms, retail pharmacies, as well as private hospitals, to further expand
\nits distribution coverage at a competitive pricing.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nClinical Research Progress<\/b><\/p>\n
\n
<\/p>\n
\nnew therapeutic areas, and will continue to collaborate with several
\nuniversities in China to conduct preclinical research of Uni-GLP in obesity, as
\nwell as to formulate a new innovative oral or 3rd generation Uni-GLP. In 2021,
\nthe Group will begin conducting bridging clinical trials for liquid form
\nUni-PTH, and wishes to submit the New Drug Application within 2021. If the process
\ngoes smoothly, it is expected that the powder form Uni-PTH will be launched in
\n2021 and liquid form Uni-PTH can be launched in as soon as 2022.<\/p>\n
\n
<\/p>\n
\n
<\/p>\n
\nUni-Bio Science<\/b>, added, “In a longer term, we aim to establish a leading drug
\ncommercialization platform in expanding its business scale in both upstream and
\ndownstream markets. In terms of upstream operations, the Group is looking for
\ncollaborations with innovative research and technology companies that are
\nequipped with pharmaceutical development capabilities. While the partner
\ncompany focuses on developing novel drugs, the Group will conduct clinical
\nresearch and be responsible for commercialization in China by leveraging its
\nextensive distribution network. In March 2021,
\nthe Group has formed a partnership with DotBio Pte. Ltd. (“DotBio”), a highly
\ninnovative biopharmaceutical company in Singapore, to co-develop next
\ngeneration, best-in-class therapeutics for patients with retinal diseases. Leveraging on DotBio’s unparalleled
\ntechnology capability in the ophthalmology space, together with the Group’s
\nextensive experience in fermentation, purification, quality assurance and
\nquality control of E.coli-expressed proteins, the Group believes that the
\npartnership is able to diversify the Group’s pipeline and capture the rising
\nneeds of the age-related macular degeneration treatment market.The Group will
\nalso expand its distribution channels by tapping into pharmaceutical
\ne-commerce. The online platforms not only allow patients to access services
\nincluding online healthcare consultation, e-prescription and drug purchase at
\nany time anywhere, but also expand doctors’ coverage and exposure by solving
\ntheir bottleneck of being in one hospital at a time. The pharmaceutical e-commerce
\narena would definitely provide doctors and patients with higher degree of
\nconvenience and cost-efficiency, and that would in turn, drive more direct
\nsales of the Group’s drugs. With our strategies to accelerate its product
\npipeline, enhance its operational efficiency and strengthen its sales network.
\nThese would in turn, promote its rapid growth and generate fruitful returns for
\nits shareholders.”<\/p>\n<\/p><\/div>\n\n
Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"